By Professor Jason Grebely

Journal articles

Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ, 2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy', International Journal of Drug Policy, 66, pp. 73 - 79, http://dx.doi.org/10.1016/j.drugpo.2019.01.011

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3

Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J, 2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, 70, pp. E333 - E334, http://dx.doi.org/10.1016/S0618-8278(19)30651-6

Catlett B; Carrera A; Starr M; Applegate TL; Lowe P; Philip Cunningham H; Grebely J, 2019, 'Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots', Journal of Clinical Virology, 112, pp. 40 - 44, http://dx.doi.org/10.1016/j.jcv.2019.01.010

Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222

Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L, 2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, 70, pp. 33 - 39, http://dx.doi.org/10.1016/j.jhep.2018.09.030

Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013

Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ, 2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, 194, pp. 487 - 494, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.007

Grebely J; Larney S; Peacock A; Colledge S; Leung J; Hickman M; Vickerman P; Blach S; Cunningham EB; Dumchev K; Lynskey M; Stone J; Trickey A; Razavi H; Mattick RP; Farrell M; Dore GJ; Degenhardt L, 2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, 114, pp. 150 - 166, http://dx.doi.org/10.1111/add.14393

Day E; Hellard M; Treloar C; Bruneau J; Martin NK; Øvrehus A; Dalgard O; Lloyd A; Dillon J; Hickman M; Byrne J; Litwin A; Maticic M; Bruggmann P; Midgard H; Norton B; Trooskin S; Lazarus JV; Grebely J, 2019, 'Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework', Liver International, 39, pp. 20 - 30, http://dx.doi.org/10.1111/liv.13949

Grebely J; Drolet M; Nwankwo C; Torrens M; Kastelic A; Walcher S; Somaini L; Mulvihill E; Ertl J; Liebert R; Litwin AH, 2019, 'Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study', International Journal of Drug Policy, 63, pp. 29 - 38, http://dx.doi.org/10.1016/j.drugpo.2018.10.012

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987

Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Grebely J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster GR; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Schnell G; Alami NN; Zhang Z; Dumas E; Dore GJ, 2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, 5, pp. ofy248, http://dx.doi.org/10.1093/ofid/ofy248

Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J, 2018, 'The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, 69, pp. 1188 - 1196, http://dx.doi.org/10.1016/j.jhep.2018.06.016

Hickman M; Larney S; Peacock A; Jones H; Grebely J; Degenhardt L, 2018, 'Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?', Addiction, 113, pp. 1768 - 1774, http://dx.doi.org/10.1111/add.14383

Peacock A; Leung J; Larney S; Colledge S; Hickman M; Rehm J; Giovino GA; West R; Hall W; Griffiths P; Ali R; Gowing L; Marsden J; Ferrari AJ; Grebely J; Farrell M; Degenhardt L, 2018, 'Global statistics on alcohol, tobacco and illicit drug use: 2017 status report', Addiction, 113, pp. 1905 - 1926, http://dx.doi.org/10.1111/add.14234

Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917

Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5

Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003

Cheng ML; Abdel-Hakeem MS; Cousineau SE; Grebely J; Marshall AD; Saeed S; Sagan SM; Shoukry NH; Feld JJ; Macparland SA, 2018, 'The 7th canadian symposium on hepatitis c virus: “toward elimination of hcv: How to get there”', Canadian Liver Journal, 1, pp. 139 - 152, http://dx.doi.org/10.3138/canlivj.2018-0018

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852

Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114

Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, 18, http://dx.doi.org/10.1186/s12879-018-3110-0

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Khan S; Bernier A; Dapp D; Fortier E; Krajden M; King A; Grebely J; Sagan SM; Cooper CL; Crawley AM, 2018, '6th canadian symposium on hepatitis C virus: Delivering a cure for hepatitis c infection—what are the remaining gaps?', Canadian Liver Journal, 1, pp. 95 - 105, http://dx.doi.org/10.3138/canlivj.1.2.008

Fortier E; Artenie A; Jutras-Aswad D; Roy É; Grebely J; Bruneau J, 2018, 'A165 SHORT INJECTION CESSATION EPISODES AS OPPORTUNITIES FOR HEPATITIS C PREVENTION', Journal of the Canadian Association of Gastroenterology, 1, pp. 286 - 287, http://dx.doi.org/10.1093/jcag/gwy008.166

Conway B; Dore GJ; Altice F; Litwin A; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C; Gendrano I; Huang H; Chen E; Nguyen B; Wahl J; Barr E; Robertson M; Platt H, 2018, 'A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)', Journal of the Canadian Association of Gastroenterology, 1, pp. 299 - 300, http://dx.doi.org/10.1093/jcag/gwy008.173

Marshall AD; Treloar C; Dore GJ; Grebely J, 2018, 'A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY', Journal of the Canadian Association of Gastroenterology, 1, pp. 419 - 419, http://dx.doi.org/10.1093/jcag/gwy008.240

Shoukry NH; Feld JJ; Grebely J, 2018, 'Hepatitis C: A Canadian perspective', Canadian Liver Journal, 1, pp. 1 - 3, http://dx.doi.org/10.3138/canlivj.1.2.001

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019

Høj SB; Minoyan N; Artenie AA; Grebely J; Bruneau J, 2018, 'The role of prevention strategies in achieving HCV elimination in Canada: What are the remaining challenges?', Canadian Liver Journal, 1, pp. 15 - 33, http://dx.doi.org/10.3138/canlivj.1.2.003

Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', The Lancet Gastroenterology and Hepatology, 3, pp. 125 - 133, http://dx.doi.org/10.1016/S2468-1253(17)30284-4

Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourlière M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy001

Jacka B; Bray BC; Applegate TL; Marshall BDL; Lima VD; Hayashi K; DeBeck K; Raghwani J; Harrigan PR; Krajden M; Montaner JSG; Grebely J, 2018, 'Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach', Journal of Viral Hepatitis, 25, pp. 28 - 36, http://dx.doi.org/10.1111/jvh.12758

Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919

Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; May M; Vickerman P, 2018, 'Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study', Journal of Hepatology, 68, pp. S179 - S180, http://dx.doi.org/10.1016/s0168-8278(18)30571-3

Fortier E; Sylvestre M-P; Artenie AA; Justras-Aswad D; Élise R; Grebely J; Bruneau J, 2018, 'One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montréal, Canada', Journal of Hepatology, 68, pp. S189 - S189, http://dx.doi.org/10.1016/s0168-8278(18)30590-7

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; Vickerman P, 2018, 'The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study', Journal of Hepatology, 68, pp. S179 - S179, http://dx.doi.org/10.1016/s0168-8278(18)30570-1

Grebely J; Applegate TL; Cunningham P; Feld JJ, 2017, 'Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis', Expert Review of Molecular Diagnostics, 17, pp. 1109 - 1115, http://dx.doi.org/10.1080/14737159.2017.1400385

Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S; Peacock A, 2017, 'Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review', The Lancet Global Health, 5, pp. e1192 - e1207, http://dx.doi.org/10.1016/S2214-109X(17)30375-3

Back to profile page